Renaissance Technologies LLC lowered its position in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 30.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 213,433 shares of the biopharmaceutical company’s stock after selling 94,600 shares during the period. Renaissance Technologies LLC’s holdings in AEterna Zentaris were worth $640,000 as of its most recent filing with the SEC.

Shares of AEterna Zentaris Inc. (NASDAQ AEZS) remained flat at $1.88 during trading on Wednesday. The stock had a trading volume of 57,469 shares. The company’s market capitalization is $30.29 million. AEterna Zentaris Inc. has a 52-week low of $0.78 and a 52-week high of $5.59. The stock’s 50-day moving average is $1.81 and its 200-day moving average is $2.02.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.05. AEterna Zentaris had a negative net margin of 1,945.78% and a negative return on equity of 514.64%. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.22 million. The firm’s revenue for the quarter was up 153.1% on a year-over-year basis. Equities research analysts expect that AEterna Zentaris Inc. will post ($1.02) EPS for the current year.

WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at

AEZS has been the subject of a number of research analyst reports. HC Wainwright lowered their price target on AEterna Zentaris from $7.50 to $3.00 and set a “buy” rating for the company in a report on Wednesday, May 10th. Maxim Group set a $2.00 price target on AEterna Zentaris and gave the stock a “buy” rating in a report on Saturday, July 1st. Finally, Zacks Investment Research raised AEterna Zentaris from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.